PMID- 34565085
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1530-6550 (Print)
IS  - 1530-6550 (Linking)
VI  - 22
IP  - 3
DP  - 2021 Sep 24
TI  - Effects of alirocumab on cardiovascular events and all-cause mortality: a 
      systematic review and meta-analysis.
PG  - 873-881
LID - 10.31083/j.rcm2203093 [doi]
AB  - Evaluation of the effects of alirocumab on cardiovascular (CV) events, CV 
      mortality and all-cause mortality. Data search was carried out using the Cochrane 
      Library, PubMed, Web of Science and Embase. The search time is up to November 18, 
      2020. All randomized clinical trials (AEs) comparing alirocumab with placebo were 
      searched. Meta-analysis was performed by Review Manager version 5.3 (The Cochrane 
      Collaboration, Copenhagen, Denmark), and the heterogeneity between studies was 
      tested by Cochrane's Q test and measured with I2 statistics. A total of 13 
      randomized controlled trials with 24,815 participants were included. Alirocumab 
      usage can considerably lower the incidence of CV events when compared to the 
      control group (risk ratio(RR) 0.89, 95% confidence interval(CI) 0.83-0.95). No 
      significant difference in CV mortality between the two groups was observed (RR 
      0.87, 95% CI 0.74-1.04). Treatment with alirocumab has been associated with a 
      major decrease in all-cause mortality compared to placebo (RR 0.80, 95% CI 
      0.66-0.96). The incidence of serious adverse events (AEs) was similar in the two 
      groups (RR 0.94, 95% CI 0.90-0.99). Alirocumab can reduce CV events and all-cause 
      mortality. The AEs were mild and tolerable.
CI  - (c) 2021 The Author(s). Published by IMR Press.
FAU - Wang, Wanting
AU  - Wang W
AD  - General Medicine, Cancer Hospital of China Medical University, Liaoning Cancer 
      Hospital & Institute, 110042 Shenyang, Liaoning, China.
FAU - Feng, Zhaoqiang
AU  - Feng Z
AD  - Hepatobiliary Pancreatic Surgery, Cancer Hospital of China Medical University, 
      Liaoning Cancer Hospital & Institute, 110042 Shenyang, Liaoning, China.
FAU - Bai, Jinghui
AU  - Bai J
AD  - General Medicine, Cancer Hospital of China Medical University, Liaoning Cancer 
      Hospital & Institute, 110042 Shenyang, Liaoning, China.
LA  - eng
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Singapore
TA  - Rev Cardiovasc Med
JT  - Reviews in cardiovascular medicine
JID - 100960007
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - PP0SHH6V16 (alirocumab)
SB  - IM
MH  - *Antibodies, Monoclonal, Humanized
MH  - *Cardiovascular Diseases/diagnosis/epidemiology/prevention & control
MH  - Cause of Death
MH  - Humans
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Alirocumab
OT  - All-cause mortality
OT  - CV events
OT  - Meta-analysis
COIS- The authors declare no conflict of interest.
EDAT- 2021/09/27 06:00
MHDA- 2021/10/29 06:00
CRDT- 2021/09/26 21:18
PHST- 2021/07/06 00:00 [received]
PHST- 2021/07/26 00:00 [revised]
PHST- 2021/08/13 00:00 [accepted]
PHST- 2021/09/26 21:18 [entrez]
PHST- 2021/09/27 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
AID - 1632453083374-816178388 [pii]
AID - 10.31083/j.rcm2203093 [doi]
PST - ppublish
SO  - Rev Cardiovasc Med. 2021 Sep 24;22(3):873-881. doi: 10.31083/j.rcm2203093.